Item 1(a).
|
Name of Issuer:
|
Protara Therapeutics, Inc. (the Issuer)
Item 1(b).
|
Address of Issuers Principal Executive Offices:
|
345 Park Avenue South, Third Floor, New York, NY 10010
Item 2(a).
|
Names of Persons Filing:
|
The names of the persons filing this report (collectively, the Reporting Persons) are:
Perceptive Advisors LLC (Perceptive Advisors)
Joseph Edelman (Mr. Edelman)
Perceptive Life Sciences Master Fund, Ltd. (the Master Fund)
Item 2(b).
|
Address of Principal Business Office or, if None, Residence:
|
The address of the principal business office of each of the Reporting Persons is:
51 Astor Place, 10th Floor
New
York, NY 10003
Perceptive Advisors is a Delaware limited liability company
Mr. Edelman is a United States citizen
The Master Fund is a Cayman Islands corporation
Item 2(d).
|
Title of Class of Securities:
|
Common Stock, $0.001 par value per share (Common Stock)
74365U 107
Item 3.
|
If this statement is filed pursuant to §§
240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
|
Not applicable.
The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this
Schedule 13G. The ownership percentages reported are based on 11,235,731 outstanding shares of Common Stock, as reported in the Issuers Form 10-Q filed on November 4, 2021.
The Master Fund directly holds 421,641 shares of Common Stock. Perceptive Advisors serves as the investment manager to the Master Fund and
may be deemed to beneficially own such shares. Mr. Edelman is the managing member of Perceptive Advisors and may be deemed to beneficially own such shares.